Meriva®, a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy.

摘要: BACKGROUND In the present study, improvement of diabetic microangiopathy and retinopathy was evaluated in 38 patients treated with a novel curcumin phospholipids delivery form (Meriva®). METHODS Diabetes diagnosed at least 5 years before inclusion all had signs retinal oedema peripheral microangiopathy. Meriva® administered dosage 2 tablets/day (each tablet containing 500 mg corresponding to 100 curcumin) for period 4 weeks addition standard management plan, while comparable group subjects (n = 39) followed plan alone. RESULTS All (treatment controls) completed follow-up period, there were no dropouts showed an optimal tolerability. At weeks, microcirculatory clinical evaluations indicated terms microangiopathy, group, significant venoarteriolar response (p<0.05) decrease score (p<0.05), sign typically associated failure response. level, high-resolution, duplex scanning, used measure flow, improvements patients. The evaluation (Steigerwalt's scale) improved visual acuity (Snellen scale). There or effects controls. CONCLUSION These preliminary observations, indicate value curcumin, when bioavailable as Meriva®, retinopathy.